Pharma — April 2023
-
(Lundbeck er på vej i samme indikation)
-
Mere migræne : IntelGenx Announces FDA Approval of RIZAFILM for the Treatment of Acute Migraine https://firstwordpharma.com/story/5728756
-
Pfizer bags FDA approval for Zavzpret migraine nasal spray https://firstwordpharma.com/story/5714749
-
FDA Grants Accelerated Approval For Biogen's ALS Drug https://www.proinvestor.com/investornyt/973749/fda-grants-accelerated-approval-for-biogens-als-drug
-
Medicinalsektor kritiserer EU-forslag om revision af regulering https://www.proinvestor.com/investornyt/974114/medicinalsektor-kritiserer-eu-forslag-om-revision-af-regulering
-
Novo-topchef ser EU-forslag som "det dummeste jeg har hørt" https://www.proinvestor.com/investornyt/974134/novo-topchef-ser-eu-forslag-som-det-dummeste-jeg-har-hort
-
Nordea hæver kursmålet på Lundbeck We raise our revenue estimates by 1-2% going forward, EBITDA estimates by 2% and EBIT estimates by 3-4% – driven by Rexulti and slightly better operating leverage. Our DCF-derived target price is raised to DKK 44 (41) and we remain buyers of the stock
-
AstraZeneca Q1 Core Profit Rises, Revenue Ex COVID-19 Up 15% At CER; Reiterates FY23 Guidance https://www.proinvestor.com/investornyt/974670/astrazeneca-q1-core-profit-rises-revenue-ex-covid-19-up-15-at-cer-reiterates-fy23-guidance
-
GSK's Respiratory Syncytial Virus Older Adult Vaccine Candidate Gets Positive CHMP Opinion https://www.proinvestor.com/investornyt/974665/gsks-respiratory-syncytial-virus-older-adult-vaccine-candidate-gets-positive-chmp-opinion
-
FDA staff flag concerns over broad use of Lynparza combo in prostate cancer FDA staff flag concerns over broad use of Lynparza combo in prostate cancer
-
Orbital bags $270 million to advance RNA-based therapeutics https://firstwordpharma.com/story/5732256?nle=113791&aid=5732256&nlc=30
-
Novartis tees up filings for iptacopan in PNH after detailing second study win https://firstwordpharma.com/story/5732247?nle=113791&aid=5732247&nlc=30
-
GSK backs full-year view as Q1 sales slip, but top forecasts
https://firstwordpharma.com/story/5732233?nle=113791&aid=5732233&nlc=30 -
Vabysmo leads growth in Roche's pharma unit during Q1 https://firstwordpharma.com/story/5732193?aid=5732193
-
Eli Lilly stiger efter opjustering trods svagere end ventet indtjening https://www.proinvestor.com/investornyt/974781/eli-lilly-stiger-efter-opjustering-trods-svagere-end-ventet-indtjening
-
Kort video - Pharma og biotek-opdatering UGE 17: Demant ' GN Store Nord ' Novo Nordisk ' Genmab ' Zealand Pharma ' Hansa Biopharma https://www.proinvestor.com/boards/112327
-
Is This Big Pharma Stock a Buy for Dividend Investors? https://www.proinvestor.com/investornyt/974944/is-this-big-pharma-stock-a-buy-for-dividend-investors
-
Lundbeck og partner får FDA-godkendelse til skizofrenimiddel https://www.proinvestor.com/investornyt/975561/lundbeck-og-partner-far-fda-godkendelse-til-skizofrenimiddel
-
JP Morgan Maintains Eli Lilly And (LLY) Overweight Recommendation https://www.proinvestor.com/investornyt/976278/jp-morgan-maintains-eli-lilly-and-lly-overweight-recommendation
-
Credit Suisse Maintains Ascendis Pharma A (ASND) Neutral Recommendation https://www.proinvestor.com/investornyt/976412/credit-suisse-maintains-ascendis-pharma-a-asnd-neutral-recommendation
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind